A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus
Phase 1/Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Cervical Intraepithelial Neoplasia
Female
Cervical Intraepithelial Neoplasia
Trial Information
A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus
Inclusion Criteria:
- 18 years of age or older
- Negative pregnancy test
- Biopsy confirmed CIN 1, 2, or 3
Exclusion Criteria:
- Pregnancy or breast feeding
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
EM-1421 #201
NCT ID:
NCT00154089
Start Date:
September 2004
Completion Date:
July 2006
Related Keywords:
- Cervical Intraepithelial Neoplasia
- cervical intraepithelial neoplasia
- CIN
- HPV
- Neoplasms
- Cervical Intraepithelial Neoplasia
- Carcinoma in Situ
Name | Location |
|---|---|
| Planned Parenthood of Delaware | Wilmington, Delaware 19801 |
| University of Maryland, Dept. of Family Medicine | Baltimore, Maryland 21201 |
